González VF, Jiménez SNG, Palacios JN, Lozano NJJ, Rubio GAF

Language: Spanish
References: 15
Page: 399-402
PDF size: 54.11 Kb.

ABSTRACT

Background: The association of diabetes mellitus and the lung tuberculosis (TBP) has been known for more than 2000 years, tuberculosis incidence in diabetic patients is reported of 1.6-2.8%; this illness is ten times more common in diabetic patients. In diabetes mellitus immunologic system is one of the most affected ones. The function of the lymphocytes T can be determined by means of the cutaneous test of slowed hypersensitivity using different antigens in front of those most of people are sensitized, one of these is PPD, which probably shows a smaller reactivity to the same one for smaller immunologic capacity when evolving the diabetes mellitus.
Objectives: To know the response to purified protein derivative in diabetic patients second to the time of diagnosis, and to identify if according to the time of diagnosis of diabetes mellitus there is a lesser reactivity to intradermoreaction.
Material and methods: 140 patients were evaluated, who were applied in the forearm 0.1 mL of PPD (5 UT) marking the place of the intradermoreaccion, and carrying out reading at the 72 h and 96 h of the application with a rule graduated in mm.
Results: In the 140 diabetic patients the mean age was of 52.7 years and in control group it was of 48.5 years. The general mean of reaction to the PPD in diabetes patients was of 6.6 (IC = 5.4-7.7) and for the controls 11.92 (IC = 10.5-13.3). The T student 5.84 (p = ‹0.05).
Conclusions: A frank decrease was observed from the reactivity to the PPD in diabetic patients according to time of evolution of the illness, indicating that a gradual deterioration exists in the immunologic response of cellular type. When being applied this cutaneous test in all the diabetic patients it is possible to detect the beginning of the immunologic deterioration.

REFERENCES

1. Hersfield E, et al. Tuberculosis: a comprehensive international approach. Marcel Dekker Inc, 1993;66:1-19.

2. Griffin J, Mackintosh L, Slobbe A, et al. Vaccine protocols to optimise the protective efficacy of BCG. Tuber Lung Dis 1999;79:135-43.

3. Barnes PF, Barrows SA. Tuberculosis in the 1990s. Ann Intern Med 1993;119:400-10.

4. Pablos MA, Blustein J, Knirsch CA. The role of diabetes mellitus in the higher prevalence of tuberculosis among Hispanics. Am J Public Health 1997;87:574-9.

5. Bonnie S, et al. The case against testing as routine adjunt to tuberculin skin testing. JAMA 2000;283:2003-7.

6. Mugusi F, Swai AB, Alberti KG, et al. Increased prevalence of diabetes mellitus in patients with pulmonary tuberculosis in Tanzania. Tubercle 1990;71:271-6.

7. Kim S. Incidence of pulmonary tuberculosis among diabetes. Tubercle and Lung Dis 1995;76:529-33.

8. Zack M. Glucose intolerance in pulmonary tuberculosis. Am Rev Resp Dis 1973;108:1164-9.

9. Oluboyo P, et al. The significance of glucose intolerance in pulmonary tuberculosis. Tubercle 1990;71:135-8.

10. Schuyler M, Niewoehner D, Inkley S, Kohn R. Abnormal lung elasticity in juvenile diabetes mellitus. Am Rev Resp Dis 1976;113:37-41.

11. Erix J. Tuberculin skin test reactivity anergy and HIV, Infection in hospitalized patients. Am J Med 1996;100:186-92.

12. Vincent L, et al. BCG vaccination and interpretation of purified protein derivate. Test Result 1997;133:916-7.

13. Sandler M. Is the lung a “target organ” in diabetes mellitus? Arch Intern Med 1990;150:1385-8.

14. Bagdade J. Impaired leukocyte function in patients with poorly controlled. Diabetes 1974;23:9-15.

15. Pérez GC, Vargas MH, Torres CA, Villarreal VH, et al. Does aging modify pulmonary tuberculosis. Chest 1999;116:961-7.